1x 베팅 주소., Ltd.

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has filed an application in Japan 1x 베팅 주소 an additional indication 1x 베팅 주소 Rexulti^® (generic name: brexpiprazole) 1x 베팅 주소 treatment of depression/depressive state (Administration should be limited to patients who showed an inadequate response to existing antidepressant therapy).

The phase 3 clinical trial evaluated the efficacy and safety of brexpiprazole as adjunctive therapy in 740 adult patients aged 20 to 64 in Japan, with MDD. Brexpiprazole was administered once daily 1x 베팅 주소 six weeks, in 1 mg or 2 mg doses, as an adjunctive therapy to SSRI or SNRI antidepressants, 1x 베팅 주소 patients who previously had inadequate responses to antidepressant monotherapy.

In the study, improvements from baseline on the primary endpoint of the Montgomery-Asberg Depression Rating Scale 1x 베팅 주소 patients receiving 1mg and 2mg of brexpiprazole 1x 베팅 주소 six weeks as adjunctive therapy were statistically greater than 1x 베팅 주소 those receiving adjunctive placebo. Brexpiprazole was generally well tolerated by trial participants, and no new safety concerns were identified.

Brexpiprazole is expected to become a new treatment option 1x 베팅 주소 patients whose depressive symptoms are not adequately relieved by existing antidepressants. Otsuka will continue to deliver innovative products to meet unmet medical needs around the world.